The unique Leadership Roundtable will explore diversity, opportunity for mentorship and career development with top leaders in the bioprocess industry.
View the full press release: 3M Biotech Forum Luncheon News Release
3M Separation and Purification Sciences Division (SPSD) with Biotech Week Boston are initiating a new event: the 3M Women in Bioprocess Roundtable Forum and Lunch, an opportunity for women scientists to share their work experiences with executive leadership in the bioprocessing industry.
Participants will network with pioneering leaders in the field, learn about bioprocess career trajectories, and create personal connections with women scientists and executives in a variety of companies.
The event will be held on September 27th where panelists will answer moderated questions from audience members registered for the event on the topic of pivotal career experiences and other key learnings for women in the industry.
Continue reading “Connecting Women in Bioprocessing with 3M at Biotech Week Boston”
By Brandy Sargent, Editor, Cell Culture Dish
At this year’s Boston Biotech Week there were many interesting talks on continuous biomanufacturing and associated new technologies. In particular, there was a great deal of discussion around how to handle difficult to produce proteins. These manufacturing challenges included proteins that were difficult to express and/or were unstable. One very interesting talk, given by Scott Waniger, Vice President, Bioservices Division, Cell Culture Company, was titled “Solving Production Challenges of Difficult-to-Express Proteins with a Scalable, Continuous Manufacturing Bioreactor: A Case Study” and focused on the use of perfusion bioreactors (hollow fiber) to create both continuous upstream production and address the issue of cost effective manufacturing of difficult to express proteins.
Mr. Waniger began the talk by describing several of the protein production challenges in the market.
Continue reading “Solve Production Challenges of Difficult to Express Proteins with Scalable, Continuous Manufacturing”
By Brandy Sargent, Editor, Cell Culture Dish
This year was the first year that the BioProcess International Conference (BPI East) became Biotech Week Boston and incorporated a Cell Therapy track. I was excited to attend and to see what the format for the new conference was going to be. I felt that the content was very relevant and covered a wide breadth of topics, from cell culture to commercial manufacturing and I was particularly interested to see how this translated to cell therapy. Overall Boston Biotech Week delivered talks focused on improving the manufacturing process for biopharmaceuticals and cell therapies, enabled industry networking opportunities, and provided the chance to see the latest products and technologies.
One area that I focused on was downstream manufacturing including recovery and purification, and drug product manufacturing including fill/finish. Continue reading “Biotech Week Boston 2016 – Downstream Coverage”
Author: Nick Hutchinson
BPOG’s Best Practice Guide
The biopharmaceutical industry is increasingly using Single-use systems (SUS) for the manufacturing of medicines. Furthermore, companies are applying the technology in applications that are more critical to patient safety. Methods for assessing risks associated with using SUS in bioprocessing need to be developed.
Miriam Monge, Marketing Director for Integrated Solutions at Sartorius Stedim Biotech moderated a session at the BioProcess International Conference & Exhibition, 2016 in which representatives from the BioPhorum Operations Group (BPOG) discussed best practices for leachables testing when implementing SUS. During her introduction, Monge highlighted the need for the various stakeholder in the industry to work together to find consensus on testing methods.
Continue reading “Leachables Testing Methods & Best Practices”
At BioProcess International 2015 we caught up with Rahul Singhvi, Chief Operating Officer at Takeda Vaccines, who told us about the general evolution of the vaccine industry over the years and what it looks like today.
Singhvi describes how companies in the vaccine space today tend to be very insular, controlling all aspects of the process, but that Takeda is taking a partnering approach, which he sees as very important.
Singhvi goes on to discuss what he feels the greatest needs and opportunities are in terms of technological innovation, development and manufacturing solutions, before making some bold predictions about the future of the vaccine industry, and the key trends and opportunities to watch out for.